Intravitreal aflibercept injection [IAI] + Sham
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nonproliferative Diabetic Retinopathy
Conditions
Nonproliferative Diabetic Retinopathy
Trial Timeline
Mar 29, 2016 → Jul 16, 2019
NCT ID
NCT02718326About Intravitreal aflibercept injection [IAI] + Sham
Intravitreal aflibercept injection [IAI] + Sham is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Nonproliferative Diabetic Retinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02718326. Target conditions include Nonproliferative Diabetic Retinopathy.
What happened to similar drugs?
1 of 1 similar drugs in Nonproliferative Diabetic Retinopathy were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02718326 | Phase 3 | Completed |
Competing Products
3 competing products in Nonproliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lucentis | Novartis | Approved | 43 |
| EYP-1901 | EyePoint Pharmaceuticals | Phase 2 | 29 |
| AKB-9778 + Placebo | EyePoint Pharmaceuticals | Phase 2 | 29 |